Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

NCT07064759 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

480

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-Related Macular Degeneration (nAMD)

Interventions

BIOLOGICAL: 4D-150 IVT (3E10 vg/eye)
BIOLOGICAL: EYLEA® (aflibercept) Injection 2 mg (0.05mL)

Sponsor

4D Molecular Therapeutics